AI modeling transforms drug development from a numbers game of screening millions of compounds to an engineering discipline. Researchers can model molecular systems upfront, understand key parameters, and design solutions for a specific problem, turning a costly screening process into a rapid, targeted design cycle.

While AI models are effective for developability properties like stability, they fall short on predicting function. Sanofi's Norbert Furtman notes that generalized affinity prediction is a 'holy grail' problem, and predicting interference with a biological pathway is even harder, as function is not solely explained by structure.

Unlike LLMs, parameter count is a misleading metric for AI models in structural biology. These models have fewer than a billion parameters but are more computationally expensive to run due to cubic operations that model pairwise interactions, making inference cost the key bottleneck.

Unlike traditional methods that simulate physical interactions like a key in a lock, ProPhet's AI learns the fundamental patterns governing why certain molecules and proteins interact. This allows for prediction without needing slow, expensive, and often impossible physical or computational simulations.

The community standard of two-angstrom accuracy for protein-ligand predictions is insufficient. At that resolution, critical details like an aromatic ring's orientation can be wrong, rendering the model's output misleading for drug design. Genesis argues one-angstrom accuracy is the minimum for practical utility.

Despite testing millions of compounds, high-throughput screening methods suffer from enormous false-positive rates. The actual predictive value for a re-synthesized molecule is extremely low, creating an opening for high-fidelity AI models to provide cleaner, more reliable predictions.

While LLMs possess vast 'Wikipedia-level' chemical knowledge, they struggle with specific, constrained tasks that expert chemists find trivial, such as designing a molecule with an exact number of atoms. This highlights a critical gap between general knowledge and applied, creative design in AI.

Beyond accelerating timelines, AI's real value lies in its ability to design molecules for targets previously considered 'hard-to-drug.' These models operate on different principles than traditional lab methods and are indifferent to historical challenges, opening up entirely new therapeutic possibilities.

The current, tangible breakthrough for AI in drug discovery is not identifying completely novel biological targets. Instead, it's rapidly designing effective molecules for known targets that have historically been considered "undruggable," compressing years of screening work into a month.